| CAS No.: | / |
|---|---|
| Formula: | / |
| EINECS: | / |
| Variety: | Lyophilized Powder |
| Feature: | Pharmaceutical Grade |
| Usage: | Lyophilized Powder |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier B7-33 Introduction
What is B7-33?
B7-33 is a soluble synthetic single-chain peptide obtained from the larger, naturally occurring protein H2-relaxin (Relaxin), which is considered to induce pleiotropic actions impacting the musculoskeletal system, cardiovascular system, and reproduction. B7-33 appears to retain the anti-fibrotic properties of Relaxin without enhancing cAMP production, it may also stimulate ERK1/2 phosphorylation and promote matrix metalloproteinase 2 (MMP2) expression and the degradation of extracellular collagen. The Relaxin family of peptides has four endogenous receptors divided into two pairs (RXFP1/2 and RXFP3/4).
B7-33 is a functionally selective agonist for the relaxin receptor 1 (RXFP1), meaning that it specifically activates this receptor and its associated signaling pathways. RXFP1 is a G-protein-coupled receptor that is activated by the hormone relaxin and its related peptides. When activated, RXFP1 stimulates the production of the second messenger cyclic adenosine monophosphate (cAMP) and the subsequent activation of protein kinase A (PKA). This leads to a variety of physiological effects, such as vasodilation, decreased blood pressure, and improved kidney function. B7-33 specifically binds to and activates RXFP1. This binding leads to the activation of the cAMP-PKA pathway, which causes vasodilation and decreased blood pressure. Additionally, B7-33 has been shown to improve kidney function through increasing the blood flow to the kidney and decreasing the expression of pro-inflammatory proteins. By binding and activating RXFP1, B7-33 may mimic the effects of relaxin and related peptides, providing a potential treatment option for hypertension, kidney disease, and heart failure.
GENERIC PEPTIDES (GMP)
cGMP peptides Manufacturing
Zhaobo Bio acquired early mastery of development and manufacturing of peptides, the short chain amino acids linked by peptide bonds that have enabled new generations of small molecule drugs that closely mimic the body's natural pathways.
Now Zhaobo Bio possesses first-class capabilities to manufacture peptides at industrial scale and in full compliance with the strictest Good Manufacturing Practice (cGMP) standards.
Upstream peptide synthesis
Zhaobo Bio production plants are endowed with state-of-the-art equipment for solvent supply, peptide synthesis, purification and isolation of active ingredients and intermediates. All equipment and containment is GMP qualified and cleaning validated. Overlapping capacities and sizes of different equipment trains facilitate a smooth scale-up for increases in demand within the product life cycle.
Downstream purification and isolation of peptides
Zhaobo Bio is committed to the systematic expansion and modernization of its purification equipment in order to ensure the efficient production of ever-increasing amounts of bulk peptide pharmaceuticals.
It uses sophisticated methods for large scale purification campaigns such as preparative high performance liquid chromatography (HPLC), ion exchange (IEX), size-exclusion chromatography (SEC), and ultra-filtration (UF/TFF). The equipment in place permits highly efficient or even continuous manufacturing of extremely pure products up to multi-kg quantities per lot.
For preparative HPLC, dynamic axial compression (DAC) stainless steel columns of up to 60 cm diameter both in batch and continuous mode are packed with the appropriate high performance silica separation phase. For low-pressure chromatography columns up to 80 cm diameter are available. Solvent delivery is ensured from eluent tank farms and containers.
The control of microbiological contamination is a prerequisite for API manufacturing. Class D (ISO 8) and C (ISO 7) clean rooms are supplied via HEPA-filtered, temperature and humidity controlled air, down-flow booths are used for minimizing microbial contamination and protecting operators. Highly active pharmaceutical ingredients are handled in integrated safety workbenches or flexible isolators reaching OEB level 4 (1-10 µg/m3).
Predefined physicochemical properties of the API can only be achieved by a carefully controlled isolation process. Besides precipitation and crystallization, lyophilization of intermediates and final API is a standard unit operation. LaixingPharma have multiple lyophilizers in different sizes (up to 300 liters) located in clean rooms.
ZhaoboBio's Peptide Plant also manufactures and offers a range of specialized services for the cGMP Small Molecules.
Small molecule production capabilities include: process development, chiral synthesis, heterocyclic chemistry, metal-catalyzed reactions, hydrogenations, oxidations and reductions using various reagents, enzymatic reactions, and high pressure reactions.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}